CD4 and COVID-19: During the COVID-19 pandemic, results from a randomized, double-blind, placebo-controlled phase I clinical trial of a COVID-19 subunit vaccine in Australia showed that after administration of a vaccine formulation containing the MF59 adjuvant, spike-specific CD4+ T cell responses and multifunctional helper T cell (Th1 and Th2) responses were enhanced.